No CrossRef data available.
Article contents
Reduced resting-state gamma-band power correlate with unaltered glutamate + glutamine levels in patients at clinical-high risk of psychosis
Published online by Cambridge University Press: 27 August 2024
Abstract
Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction
There is growing evidence of excitation / inhibition (E/I) balance abnormalities in schizophrenia, which might be associated with abnormal gamma frequency oscillations and glutamate concentrations. However, to the best of our knowledge, only one multimodal study have examined such associations between EEG and metabolite characteristics in patients at clinical-high risk of psychosis (CHR) so far.
Objectives
We aimed to investigate potential associations between GLX (glutamate + glutamine) levels and resting-state gamma-band power in CHR individuals and healthy controls (HC).
Methods
Twenty right-handed male patients (16-27 years, mean age 19.9 ± 2.7) fulfilling CHR criteria and 19 healthy male controls (16-27 years, mean age 21.6 ± 3.6) underwent resting-state EEG (16 leads; 10−20 system) and MR spectroscopy at 3T MRI scanner with voxels of 30×30×30mm located in left and right medial prefrontal cortex. Spectral analysis with estimation of gamma-band power (30-45 Hz) were conducted. MEGA-PRESS acquisitions were analyzed with jMRUi (ver. 5.1 Alpha), levels of GLX were calculated as a ratios to creatine + phosphocreatine (GLX/Cr). Gamma-band (30-45 Hz) spectral power and GLX/Cr were compared between groups. Correlations between EEG and metabolite data were analyzed with regression model including age and chlorpromazine equivalents as covariates.
Results
Compared to healthy controls, patients showed reduced spectral gamma-band power in 6 leads (Table). No alterations in GLX/Cr were detected. Positive correlations between altered gamma-power in all leads (except Cz) and GLX/Cr in left medial prefrontal cortex were revealed in CHR (F3: r=0.51, p=0.006; F8: r=0. 54, p=0.004; C3: r=0.37, p=0.037; Pz: r=0.51, p=0.039; P4: r=0.56, p=0.009). No correlations in HC group were found. Chlorpromazine equivalents did not correlate with GLX/Cr of gamma power in CHR group.Table.
Results of between-group comparisons corrected for multiple comparisons
| Lead | CHR Mean±SD | HC Mean±SD | p-value | F | Cohen’s d | Cohen’s d CI 95% |
|---|---|---|---|---|---|---|
| F3 | 0.97±0.62 | 1.4±0.64 | 0.0097 | 7.2 | -0.69 | -1.22 -0.16 |
| F8 | 0.84±0.61 | 1.45±1.03 | 0.0072 | 7.8 | -0.71 | -1.24 -0.19 |
| C3 | 0.97±0.55 | 1.44±0.64 | 0.0026 | 9.9 | -0.79 | -1.32 -0.27 |
| Cz | 1.03±0.61 | 1.42±0.52 | 0.0074 | 7.7 | -0.70 | -1.22 -0.18 |
| Pz | 1.17±0.7 | 1.62±0.63 | 0.0098 | 7.1 | -0.68 | -1.2 -0.16 |
| P4 | 1.04±0.66 | 1.53±0.66 | 0.0051 | 8.5 | -0.74 | -1.27 -0.22 |
Conclusions
The findings suggest that clinical-high risk of psychosis is associated with widespread alterations in resting-state gamma-band power. Positive correlations of such alterations with GLX/Cr and absence of such correlations in HC group are presumably indicative of disturbances in the excitation / inhibition balance in CHR individuals.
This study was supported by RFBR grant 19-29-10040
Disclosure of Interest
None Declared
- Type
- Abstract
- Information
- European Psychiatry , Volume 67 , Special Issue S1: Abstracts of the 32nd European Congress of Psychiatry , April 2024 , pp. S615
- Creative Commons
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.- Copyright
- © The Author(s), 2024. Published by Cambridge University Press on behalf of European Psychiatric Association
You have
Access
Open access
Comments
No Comments have been published for this article.